Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

Table 1

Patient demographics and baseline clinical characteristics.

	Total ()	Men ()	Women ()	value
Age (y)	39.56 ± 9.11	39.63 ± 8.15	39.53 ± 9.59	0.954
Duration of disease (y)	11.37 ± 6.74	11.01 ± 6.13	10.62 ± 7.44	0.759
Number of previous DMT	1.51 ± 0.83	1.47 ± 0.80	1.54 ± 0.85	0.644
Duration of DMT (months)	59.52 ± 45.49	32.02 ± 46.45	58.28 ± 45.21	0.647
Previous immunosuppressant therapy	19.01%	25.53%	15.78%	0.164
Previous use of natalizumab	19.71%	12.76%	23.15%	0.143
In the year prior to commencing fingolimod
EDSS score	2.52 ± 1.02	2.36 ± 1.02	2.60 ± 1.08	0.222
ARR	1.14 ± 0.71	1.06 ± 0.60	1.18 ± 0.78	0.373
New or newly enlarging T2 lesions	72.3%	70.2%	73.4%	0.690
Gadolinium enhancing lesions	49.6%	44.7%	52.1%	0.404

Data are mean ± SD unless otherwise indicated.
ARR: annualized relapse rate.
DMT: disease modifying therapy.
EDSS: Expanded Disability Status Scale.